Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401

NCT02363439 is registered in ClinicalTrials.gov with Idera Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02363439
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02363439 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401
Lead sponsor
Idera Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2014
Completion date
December 31, 2016
Enrollment
5 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

waldenstrom's macroglobulinemia